AMAG Pharmaceuticals announced it has awarded Dr. Jacqueline Parchem, assistant professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at McGovern Medical School, a grant to help further research in fetal development.
Parchem is one of four independent researchers awarded grants totaling $300,000 by the biopharmaceutical company as part of its ongoing support of maternal and neonatal health. The 2017 grant recipients were selected by an independent external review panel of several maternal fetal medicine specialists (MFM) chaired by Dr. George Saade, professor of Obstetrics/Gynecology at The University of Texas Medical Branch (UTMB).
Parchem is researching the role of amniotic fluid exosomes in fetal development and placental membrane health. She joined UTHealth last fall and attended medical school at the University of California San Francisco School of Medicine. She completed her residency in the Department of Obstetrics, Gynecology and Reproductive Sciences at UCSF and completed fellowships in maternal fetal medicine there and at Baylor College of Medicine.
“Research is an important way to advance our understanding of preterm birth, which we hope will ultimately lead to the reduction of babies born too early in our country,” Saade said in a press release. “The review committee was extremely pleased with the number, quality and novelty of the applications this year. Support from organizations like AMAG is critical, enabling these researchers to continue their work and expand our knowledge about preterm birth.”